Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686951 | 0.90 | GAA (0.55) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL1920939 | 0.85 | GAA (0.59) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL6581527 | 0.82 | GAA (0.51) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL20163720 | 0.78 | GAA (0.47) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL371723 | 0.78 | GAA (0.56) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL28104992 | 0.77 | GAA (0.60) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL11355073 | 0.76 | GAA (0.54) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL28612690 | 0.75 | GAA (0.62) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL28349386 | 0.75 | GAA (0.62) | GAAKMT2ATSHRMEN1CYP2D6 | |
| SCHEMBL29876548 | 0.75 | GAA (0.54) | GAAKMT2ATSHRMEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1716135-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | Pfizer Limited (GB) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | GAA 3978/4885KMT2A 2570/4885TSHR 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.